

[Securities Litigation Against Life Sciences Companies 2024 Year in Review](#)




Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies.

In the following sections, we analyze data and trends in securities class actions across all industries and in the life sciences industry in particular. We then highlight important 2024 decisions issued by federal courts in securities cases brought against life sciences companies and their officers.

Read the full report [here](#).

[2023-2024 Key Trends and Updates: Securities Litigation Against Life Sciences Companies Webinar](#)



In this webinar, [Caroline Bullerjahn](#), [Tucker DeVoe](#), and [Justin Ward](#) from Goodwin, and [Frank Schneider](#) from Cornerstone Research will discuss key updates and recent trends concerning securities class actions filed against publicly traded pharmaceutical, biotechnology, medical device and healthcare product and services companies (collectively, “life sciences companies”), which continue to be a primary target of the plaintiffs’ bar. While securities class action litigation against life sciences companies decreased slightly in 2023 compared to 2022, life sciences companies remain by far the most targeted sector for these suits, and the total number of securities class action suits filed against life sciences companies remains above the long-run historical average (40 filings in 2023 compared to 37 filings per year in from 1997-2022).

In addition to analyzing these overall trends, we will:

- examine data for class action filings in 2023 and trends based upon such data, focusing on filings


against life sciences companies;

- review several significant, impactful recent decisions issued by federal courts particularly relevant to life sciences companies;
- provide in-depth analysis of the potential implications of these decisions, which involve challenges that life sciences companies often face; and
- discuss practical steps you can take to make informed choices related to your business, including your public disclosures.

This program is pending one hour CLE credit in California, New York, New Jersey, and/or Pennsylvania.

This webinar is scheduled for Wednesday, April 3rd from 2:30 – 3:30 PM ET. Please [register](#) here.

Webinar: 2022-2023 Key Trends and Updates: Securities Litigation Against Life Sciences Companies



Publicly traded life sciences companies continue to be the primary target of the plaintiffs' bar, facing far more securities class action lawsuits compared to other sectors. What does this mean for your business, and what practical steps can you take to make informed choices? Join [Caroline Bullerjahn](#), [Courtney Orazio](#), and [John Barker](#) as they speak to these pressing issues in Goodwin's webinar, "2022-2023 Key Trends and Updates: Securities Litigation Against Life Sciences Companies," taking place on Thursday, June 8th from 2:30 – 3:30 PM ET.

[Register](#) today!

Goodwin Webinar Series: Life Sciences Disputes



Goodwin is pleased to invite you to our Life Sciences Disputes webinar series, which will highlight current topics across our Securities Litigation and Antitrust practice areas that affect life sciences companies.

Trends and Hot Topics in Securities Litigation and SEC Enforcement for the Life Sciences Industry

November 9, 2021 - 1:00 pm - 2:00 pm EST

Life sciences and biotech companies are particularly vulnerable to securities class actions due to the variety of event-driven disclosures and the inherently volatile nature of their stock prices. Because of this, over the past several years the biotech and life sciences industries have been the most targeted industries by plaintiffs' lawyers and a consistent focus of the SEC. Our panel will address the unique securities law disclosure issues facing life sciences companies, particularly with respect to managing risk arising from disclosures of clinical trial results and communications with FDA.

[For more information and to register.](#)

FTC Antitrust Lessons Learned for Life Sciences Companies

November 18, 2021 - 2:00 pm - 3:00 pm EST

Over the past several months, Federal Trade Commission (FTC) oversight has been unprecedentedly high when it comes to exit transactions. Additionally, rules are changing in real time that affect M&A transactions and licensing collaborations, especially in the life sciences industry.

[For more information and to register.](#)

SEC Chairman's Comments Signal Likely Changes to Rule 10b5-1 Trading Plans



Rule 10b5-1 trading plans have faced increased scrutiny since the onset of the COVID-19 pandemic and the corresponding public focus on stock sales by executives of public [life sciences companies](#). On June 7, 2021, SEC Chairman Gary Gensler continued that scrutiny when he delivered prepared [remarks](#) to the *Wall Street Journal's* CFO Network Summit concerning Rule 10b5-1 trading plans and his view that “these plans have led to real cracks in our insider trading regime.” Mr. Gensler outlined four potential reforms that the SEC staff is considering to address those “cracks”.

Read the full insight [here](#).

[2020 Year in Review: Securities Litigation Against Life Sciences and Healthcare Companies](#)



Despite the turmoil and disruption of 2020, plaintiffs’ lawyers and courts appear to have adapted readily to our “new normal.” Although at lower rates than previous years, plaintiffs’ firms continued to file securities class actions against publicly traded pharmaceutical, biotechnology, medical device and healthcare product and services companies in 2020, while courts continued to issue detailed, substantive decisions in these actions. The number of class action filings in state and federal courts from last year shows a 22% decline from a record level in 2019 – a decrease for the first time since 2016, but still far higher than the 1997-2019 average.

In Goodwin’s fifth annual Year in Review publication, we focus on active jurisdictions that are geographic epicenters for life sciences and healthcare companies: the First Circuit and the District of Massachusetts; the Second Circuit and New York District Courts; and the Ninth Circuit and California District Courts. In our analysis, we summarize key decisions issued in these jurisdictions

during 2020 in class actions against life sciences and healthcare companies, as well as cases to watch in 2021.

[Read the Report.](#)